These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22733388)

  • 1. Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
    Thomas S; Paul SK; Shandilya S; Agarwal A; Saxena N; Awasthi AK; Matta Hb; Vir D; Mathela CS
    Analyst; 2012 Aug; 137(15):3571-82. PubMed ID: 22733388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
    Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
    J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of RP-UPLC method for the determination of darifenacin hydrobromide, its related compounds and its degradation products using design of experiments.
    Murthy MV; Krishnaiah Ch; Srinivas K; Rao KS; Kumar NR; Mukkanti K
    J Pharm Biomed Anal; 2013 Jan; 72():40-50. PubMed ID: 23146225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, synthesis and quantification of process-related impurities in auraptene.
    Li YG; Chen HF; Tu MZ; Zhang PZ; Wang XY; Yuan JB; Yang WL
    J Pharm Biomed Anal; 2011 Sep; 56(2):191-9. PubMed ID: 21705169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate.
    Chitturi SR; Somannavar YS; Peruri BG; Nallapati S; Sharma HK; Budidet SR; Handa VK; Vurimindi HB
    J Pharm Biomed Anal; 2011 Apr; 55(1):31-47. PubMed ID: 21316175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of liquid chromatography/tandem mass spectrometric molecular fingerprinting for the rapid structural identification of pharmaceutical impurities.
    Li M; Wang X; Chen B; Lin M; Buevich AV; Chan TM; Rustum AM
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3533-42. PubMed ID: 19844969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate.
    Raj TJ; Bharathi Ch; Kumar MS; Prabahar J; Kumar PN; Sharma HK; Parikh K
    J Pharm Biomed Anal; 2009 Jan; 49(1):156-62. PubMed ID: 19056198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
    Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
    J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
    Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
    J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced degradation of fentanyl: identification and analysis of impurities and degradants.
    Garg A; Solas DW; Takahashi LH; Cassella JV
    J Pharm Biomed Anal; 2010 Nov; 53(3):325-34. PubMed ID: 20462721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
    Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, synthesis and structural characterization of process related and degradation impurities of acrivastine and validation of HPLC method.
    Kumar A; Devineni SR; Dubey SK; Kumar P; Srivastava V; Ambulgekar G; Jain M; Gupta DK; Singh G; Kumar R; Hiriyanna SG; Kumar P
    J Pharm Biomed Anal; 2017 Jan; 133():15-26. PubMed ID: 27969063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparative isolation and structural elucidation of impurities in fluconazole by LC/MS/MS.
    Dongre VG; Karmuse PP; Ghugre PD; Salunke SM; Panda N; Kumar A
    J Pharm Biomed Anal; 2006 Sep; 42(3):334-40. PubMed ID: 16757140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination and characterization of degradation products of anastrozole by LC-MS/MS and NMR spectroscopy.
    Sitaram C; Rupakula R; Reddy BN
    J Pharm Biomed Anal; 2011 Dec; 56(5):962-8. PubMed ID: 21890298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.